{"title":"香港某地区公立医院接受氯氮平治疗的成年精神病门诊患者的便秘发生率。","authors":"Eric Wai-Fung Lam, Brian Pak-In Ip","doi":"10.1002/hup.2897","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To determine the occurrence of constipation in local patients on clozapine treatment, and to compare the demographical and clinical characteristics of patients on clozapine treatment with or without constipation.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This is a cross-sectional, observational study. All adult psychiatric out-patients on clozapine treatment attending follow-up at a regional hospital were recruited for clinical interview and medical record review. The Enhanced Asian Rome III Questionnaire (EAR3Q) was used to define patients with constipation. The Bristol Stool Form Scale (BSFS) was used to assess stool form. The Brief Psychiatric Rating Scale-Anchored (BPRS-A) was used to measure psychiatric symptoms. The Brief Medication Adherence Scale (BMAS) was used to assess treatment adherence. Logistic regression was conducted to identify independent associating factors of constipation in patients on clozapine treatment.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The prevalence of constipation in patients on clozapine treatment was 26.3%, (95% CI [21.5%, 31.6%]). Independent associating factors included disorder of psychological development (aOR = 6.98, 95% CI [1.24, 39.18]), anxiety (very mild: aOR = 9.23, 95% CI [2.59, 32.87]; mild: aOR = 2.66, 95% CI [1.26, 5.62]), prescription with combination of laxatives (aOR = 0.40, 95% CI [0.17, 0.95]), and concomitant use of amisulpride (aOR = 2.52, 95% CI [1.09, 5.82]), quetiapine (aOR = 5.92, 95% CI [1.11, 31.56]) and metamucil (aOR = 9.30, 95% CI [1.53, 56.58]).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study examined the prevalence of clozapine-associated constipation in Hong Kong using a validated questionnaire. The identification of independent factors associated with constipation could facilitate better risk stratification and risk modification in clinical practice.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"39 5","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The prevalence of constipation in adult psychiatric out-patients on clozapine treatment at a regional public hospital in Hong Kong\",\"authors\":\"Eric Wai-Fung Lam, Brian Pak-In Ip\",\"doi\":\"10.1002/hup.2897\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To determine the occurrence of constipation in local patients on clozapine treatment, and to compare the demographical and clinical characteristics of patients on clozapine treatment with or without constipation.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This is a cross-sectional, observational study. All adult psychiatric out-patients on clozapine treatment attending follow-up at a regional hospital were recruited for clinical interview and medical record review. The Enhanced Asian Rome III Questionnaire (EAR3Q) was used to define patients with constipation. The Bristol Stool Form Scale (BSFS) was used to assess stool form. The Brief Psychiatric Rating Scale-Anchored (BPRS-A) was used to measure psychiatric symptoms. The Brief Medication Adherence Scale (BMAS) was used to assess treatment adherence. Logistic regression was conducted to identify independent associating factors of constipation in patients on clozapine treatment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The prevalence of constipation in patients on clozapine treatment was 26.3%, (95% CI [21.5%, 31.6%]). Independent associating factors included disorder of psychological development (aOR = 6.98, 95% CI [1.24, 39.18]), anxiety (very mild: aOR = 9.23, 95% CI [2.59, 32.87]; mild: aOR = 2.66, 95% CI [1.26, 5.62]), prescription with combination of laxatives (aOR = 0.40, 95% CI [0.17, 0.95]), and concomitant use of amisulpride (aOR = 2.52, 95% CI [1.09, 5.82]), quetiapine (aOR = 5.92, 95% CI [1.11, 31.56]) and metamucil (aOR = 9.30, 95% CI [1.53, 56.58]).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This study examined the prevalence of clozapine-associated constipation in Hong Kong using a validated questionnaire. The identification of independent factors associated with constipation could facilitate better risk stratification and risk modification in clinical practice.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13030,\"journal\":{\"name\":\"Human Psychopharmacology: Clinical and Experimental\",\"volume\":\"39 5\",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-04-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Psychopharmacology: Clinical and Experimental\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hup.2897\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2897","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的确定当地接受氯氮平治疗的患者中发生便秘的情况,并比较接受氯氮平治疗的患者中存在或不存在便秘的人口统计学和临床特征:这是一项横断面观察研究。方法:这是一项横断面观察性研究。研究人员招募了在一家地区医院接受氯氮平治疗并接受随访的所有成年精神病门诊患者,对他们进行临床访谈和病历审查。增强型亚洲罗马III问卷(EAR3Q)用于界定便秘患者。布里斯托粪便形态量表(BSFS)用于评估粪便形态。简明精神病评定量表-带刻度(BPRS-A)用于测量精神症状。简明用药依从性量表(BMAS)用于评估治疗依从性。进行逻辑回归以确定氯氮平治疗患者便秘的独立相关因素:结果:氯氮平治疗患者的便秘发生率为26.3%(95% CI [21.5%, 31.6%])。独立的相关因素包括心理发育障碍(aOR = 6.98,95% CI [1.24,39.18])、焦虑(极轻度:aOR = 9.23,95% CI [2.59,32.87];轻度:aOR = 2.66,95% CI [1.26,5.62])、处方联合用药(aOR = 6.98,95% CI [1.24,39.18])。62]),处方中联合使用泻药(aOR = 0.40,95% CI [0.17,0.95]),同时使用氨磺必利(aOR = 2.52,95% CI [1.09,5.82])、喹硫平(aOR = 5.92,95% CI [1.11,31.56])和美他美嗪(aOR = 9.30,95% CI [1.53,56.58]):本研究使用有效问卷调查了香港氯氮平相关性便秘的发病率。确定与便秘相关的独立因素有助于在临床实践中更好地进行风险分层和风险调整。
The prevalence of constipation in adult psychiatric out-patients on clozapine treatment at a regional public hospital in Hong Kong
Objective
To determine the occurrence of constipation in local patients on clozapine treatment, and to compare the demographical and clinical characteristics of patients on clozapine treatment with or without constipation.
Methods
This is a cross-sectional, observational study. All adult psychiatric out-patients on clozapine treatment attending follow-up at a regional hospital were recruited for clinical interview and medical record review. The Enhanced Asian Rome III Questionnaire (EAR3Q) was used to define patients with constipation. The Bristol Stool Form Scale (BSFS) was used to assess stool form. The Brief Psychiatric Rating Scale-Anchored (BPRS-A) was used to measure psychiatric symptoms. The Brief Medication Adherence Scale (BMAS) was used to assess treatment adherence. Logistic regression was conducted to identify independent associating factors of constipation in patients on clozapine treatment.
Results
The prevalence of constipation in patients on clozapine treatment was 26.3%, (95% CI [21.5%, 31.6%]). Independent associating factors included disorder of psychological development (aOR = 6.98, 95% CI [1.24, 39.18]), anxiety (very mild: aOR = 9.23, 95% CI [2.59, 32.87]; mild: aOR = 2.66, 95% CI [1.26, 5.62]), prescription with combination of laxatives (aOR = 0.40, 95% CI [0.17, 0.95]), and concomitant use of amisulpride (aOR = 2.52, 95% CI [1.09, 5.82]), quetiapine (aOR = 5.92, 95% CI [1.11, 31.56]) and metamucil (aOR = 9.30, 95% CI [1.53, 56.58]).
Conclusion
This study examined the prevalence of clozapine-associated constipation in Hong Kong using a validated questionnaire. The identification of independent factors associated with constipation could facilitate better risk stratification and risk modification in clinical practice.
期刊介绍:
Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal:
-All aspects of clinical psychopharmacology-
Efficacy and safety studies of novel and standard psychotropic drugs-
Studies of the adverse effects of psychotropic drugs-
Effects of psychotropic drugs on normal physiological processes-
Geriatric and paediatric psychopharmacology-
Ethical and psychosocial aspects of drug use and misuse-
Psychopharmacological aspects of sleep and chronobiology-
Neuroimaging and psychoactive drugs-
Phytopharmacology and psychoactive substances-
Drug treatment of neurological disorders-
Mechanisms of action of psychotropic drugs-
Ethnopsychopharmacology-
Pharmacogenetic aspects of mental illness and drug response-
Psychometrics: psychopharmacological methods and experimental design